What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo”In the company’s words, NCT07108894 on ClinicalTrials.gov
Coming up1
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Apr 2027 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026